This study is limited by implementation at a single tertiary center. However, improved value with use of our order set despite low usage of dermatologic and vascular medicine consultations suggests effectiveness even in hospitals lacking dermatologic and vascular medicine consultants. Given the slight decrease in readmissions in 2017 in our control group, institutional initiatives to limit readmission for comorbidities might also confound our results. Materials for the order set and tools developed for this study are freely available at
Sunburn prevalence among US adults, National Health Interview Survey 2005, 2010, and 2015
To the Editor: Sunburn is a biologic indicator of acute overexposure to ultraviolet (UV) radiation, and sunburn at any age is associated with an increased risk for melanoma. 1 Tracking changes in the national prevalence of sunburn over time can provide insight to our nation's progress toward increasing adequate use of sun protection and reducing skin cancer risk at a population level. 2 We examined changes over time in sunburn among US adults during 2005-2015. We analyzed data from the 2005, 2010, and 2015 National Health Interview Survey, a cross-sectional, nationally representative sample of the US civilian population aged $18 years (https://www.cdc.gov/ nchs/nhis/). Respondents were asked to report the number of sunburns they experienced during the preceding 12 months. We estimated the percentage of adults who experienced $1 sunburn each year and the mean number of sunburns among those who were sunburned overall and by sex, age group, race/ethnicity, and US region. We assessed differences in sunburn between survey years by using logistic regressions to calculate adjusted prevalence ratios overall and for each demographic subgroup. Annual unconditional response rates were 55.2%-69.0%, and sample sizes were 27,157-33,672 persons. We used SAS-callable SUDAAN version 11.0 (Research Triangle Institute, Research Triangle Park, NC) for the analyses to account for the complex sampling design and for nonresponse.
Each year, more than one third of adults experienced sunburn ( (Fig 1) . There were no significant changes in the mean number of sunburns over time.
Study limitations include reliance on self-reported information, which is subject to error, and generalizability to only the noninstitutionalized, civilian adult population. The large sample size warrants caution when interpreting statistically significant results with small absolute differences between years.
Overall, we found little change in sunburn prevalence during 2005-2015. Although sunburn is most prevalent among non-Hispanic white adults, heterogeneity in skin type exists within racial and ethnic groups, and these data indicate that all demographic groups experience preventable overexposure to UV radiation. Without future decreases in sunburn, skin cancer rates will likely continue to increase in the decades to come. APRs were adjusted for demographic characteristics by using logistic regression models with predicted marginal probabilities. The APRs for total were adjusted for sex, age groups, race/ethnicity, and US region in the model. The APRs for male and female were adjusted for age groups, race/ethnicity, and US region in the model. The APRs for the 5 age groups were adjusted for sex, race/ethnicity, and US region in the model. The APRs for the racial/ethnic groups were adjusted for sex, age groups, and US region in the model. The APRs for the US regions were adjusted for sex, age groups, and race/ethnicity. The category other non-Hispanic races included non-Hispanic respondents who were American Indian, Alaska Native, Asian, or multiple races. APR, Adjusted prevalence ratio. *APR is statistically significant (P \ .01). To the Editor: Although natalizumab is approved for treating multiple sclerosis, 1 reports have raised concern about malignant melanoma (MM) after natalizumab exposure. 2, 3 The aim of this study was to determine if an association was detectable for MM after natalizumab exposure in patients with multiple sclerosis.
Using RADAR methodology, 4 we searched the following databases: FDA Adverse Event Reporting System (FAERS), EudraVigilance (European Medicines Agency), and the Northwestern Medicine Enterprise Data Warehouse (NMEDW).
The FAERS search (January 2004-June 2014) comprised terms related to MM combined with natalizumab. The proportional reporting ratio (PRR) was then calculated to determine if a safety signal (defined as [3 events, chi-squared result [4, and PRR [2) was detectable. 5 We extracted data (January 2004-December 2015) from the NMEDW, a large, urban, Midwestern US population ([4 million patients, including a National Cancer Instituteedesignated comprehensive cancer center) for multiple sclerosis patients exposed to natalizumab who had a diagnosis for MM A signal was detected in the FAERS database (PRR 2.42, 95% confidence interval 2.10-2.8) from 205 reports of MM subsequent to natalizumab exposure. In the NMEDW, of 5097 multiple sclerosis patients, 192 were exposed to natalizumab with 3 (1.6%) subsequently receiving a MM diagnosis (a significant association, Fisher's exact test, P \ .0001). The EudraVigilance database comprised 78 reports of MM after natalizumab exposure.
These findings substantiate a recent study that linked natalizumab exposure to MM through FAERS analysis.
2 Natalizumab-exposed patients had a younger median age at MM diagnosis compared with the general (nonenatalizumab-exposed) US population. 2 Mechanisms underlying the association for MM with natalizumab are incompletely understood; however, it seems that the drug's inhibitory effects on 4 -integrins might relate to MM evolution because melanoma cells expressing 4 1 have increased homotypic intercellular adhesion and decreased ability to invade the extracellular matrix. 3 Inhibition of integrins with natalizumab might increase invasive potential. Of importance, these findings suggest that MM occurrence after natalizumab exposure might be biologically dissimilar to MM de novo.
Limitations include possible reporting bias within FAERS and possible redundancy in the EudraVigilance and FAERS databases. Moreover, signals detected from reporting in FAERS constitute reporting ratios and cannot be interpreted as incidence rates or risk ratios. 5 Furthermore, NMEDW database's small sample prevented additional analyses for potential confounding factors. Because determination of PRR requires the total number of adverse events reported for the drug of interest, number of adverse events of interest for the drug of interest, total number of all other adverse events, and the total number of all other drugs, 5 PRR could not be calculated with EudraVigilance data.
These findings demonstrate a detectable safety signal within FAERS and a statistically significant association for MM after natalizumab exposure in NMEDW; the EudraVigilance data was not inconsistent with these findings, with 78 reports being found. Of note, the full prescribing information for natalizumab does not refer to melanoma, 1 but enhanced monitoring of exposed patients seems warranted, especially for those at high risk for melanoma. 
